Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients With Generalized Myasthenia Gravis

NCT07596901 is registered in ClinicalTrials.gov with Aurinia Pharmaceuticals Inc. as lead sponsor.

NCT NCT07596901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07596901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients With Generalized Myasthenia Gravis
Lead sponsor
Aurinia Pharmaceuticals Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 22, 2026
Completion date
March 2, 2029
Enrollment
81 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

myasthenia gravis, generalized